Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity; Paraproteinaemia
- Focus Therapeutic Use
- 17 Sep 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 02 Jan 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 02 Jan 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2021.